Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
1. Epcoritamab shows feasibility for outpatient treatment of R/R DLBCL. 2. 92% of patients received their first full dose in outpatient settings. 3. Overall response rate was 64.3%, with 47.6% achieving complete response. 4. Adverse event profile remains consistent with previous studies. 5. New outpatient approach may enhance treatment accessibility for DLBCL patients.